Troponin Test: Cardiac Injury Marker for Heart Attack Diagnosis

Cardiac troponin (cTnI and cTnT) is the gold-standard biomarker for diagnosing acute myocardial infarction (AMI). Released from cardiomyocytes when the cell membrane is disrupted, troponin provides both high sensitivity (detects even minor myocardial injury) and high cardiac specificity (cardiac isoforms are structurally distinct from skeletal muscle troponin). The introduction of high-sensitivity troponin (hs-cTn) assays has transformed the emergency diagnosis of acute MI, enabling 0h/1h and 0h/2h rapid rule-in/rule-out algorithms.

Table of Contents

1. Overview — What Is Cardiac Troponin?
2. Biochemistry: The Troponin Complex
3. High-Sensitivity Troponin Assays
4. Reference Ranges and the 99th Percentile
5. Rapid Rule-In and Rule-Out Algorithms
6. Type 1 vs. Type 2 Myocardial Infarction
7. Non-Coronary Causes of Troponin Elevation
8. Key Research and Citations
9. Connections
10. Featured Videos

Overview — What Is Cardiac Troponin?

Troponin entered clinical use as a cardiac biomarker in the 1990s, rapidly replacing CK-MB (creatine kinase MB isoform) as the preferred marker for MI diagnosis. The 2000 ESC/ACC consensus redefined MI as any troponin elevation above the 99th percentile of a reference population accompanied by a rise and/or fall pattern — the "Universal Definition of MI." This definition has since been refined in three subsequent universal definitions (2007, 2012, 2018).

Troponin measures myocardial cell death or injury; it does not diagnose the cause of that injury, which may be coronary atherosclerosis, cardiomyopathy, myocarditis, sepsis, or many other conditions. Distinguishing the cause of troponin elevation requires integrating clinical history, ECG findings, echocardiography, and — when appropriate — coronary angiography.

Two cardiac-specific isoforms are measured in clinical practice:

• Cardiac troponin I (cTnI): Inhibitory subunit, 31 kDa, with a unique 31-amino acid N-terminal extension that distinguishes it from skeletal muscle TnI.
• Cardiac troponin T (cTnT): Tropomyosin-binding subunit, 36 kDa, with a cardiac-specific epitope in its N-terminal region. The Roche Elecsys hs-cTnT assay is the most widely studied platform globally.

Both are measured using highly specific monoclonal antibodies that do not cross-react with skeletal muscle isoforms under normal conditions, making them cardiac-specific rather than merely cardiac-sensitive.

Back to Table of Contents

Biochemistry: The Troponin Complex

The troponin complex is a trimeric regulatory protein embedded in the thin filament of striated muscle. It sits at the core of the calcium-regulated actin-myosin contraction cycle. The three subunits each have distinct structural and functional roles:

• Troponin T (TnT): The tropomyosin-binding subunit. Anchors the entire troponin complex to tropomyosin along the thin filament. Its elongated tail (N-terminal) extends along tropomyosin, while its globular C-terminal domain interacts with TnI and TnC.
• Troponin I (TnI): The inhibitory subunit. At low intracellular calcium, TnI's inhibitory region binds actin, holding tropomyosin over the myosin-binding sites and preventing contraction. TnI also has a cardiac-specific N-terminal extension (residues 1–31) that is phosphorylated by protein kinase A (PKA) in response to beta-adrenergic stimulation, modulating calcium sensitivity.
• Troponin C (TnC): The calcium-sensing subunit. Contains four EF-hand calcium-binding motifs; sites III and IV (C-terminal) are high-affinity structural sites always occupied; site II (N-terminal) is the regulatory low-affinity site that binds calcium during depolarization and triggers the conformational cascade.

Contraction cycle: When intracellular calcium rises during an action potential, calcium binds TnC's regulatory site II, inducing a conformational change that causes TnC to bind TnI's inhibitory domain. This releases TnI from actin, allowing tropomyosin to shift and expose myosin-binding sites on actin — permitting cross-bridge cycling and muscle contraction. When calcium is re-sequestered by SERCA into the sarcoplasmic reticulum, TnC releases calcium, TnI rebinds actin, and tropomyosin re-covers the myosin-binding sites.

Release pattern in MI: When cardiomyocytes sustain irreversible injury (ischemia beyond ~20–40 minutes), the sarcolemmal membrane becomes disrupted. The cytoplasmic pool of troponin (a small free pool representing ~2–8% of total cardiomyocyte troponin) is released first, causing the early rise in serum troponin. Subsequently, the structurally bound trimeric complexes are degraded and released, explaining the prolonged elevation — cTnI may remain elevated for 7–14 days after a large MI; cTnT for up to 14 days. This slow washout is diagnostically important: a patient presenting days after chest pain may still have elevated troponin from the original event.

Back to Table of Contents

High-Sensitivity Troponin Assays

The generation of troponin assays is defined not by a specific technology but by analytical performance criteria established by the IFCC (International Federation of Clinical Chemistry):

• Conventional (contemporary) assays: CV >10% at the 99th percentile; detectable troponin in <50% of healthy individuals. Examples: older Abbott AxSYM cTnI, first-generation Roche Elecsys cTnT.
• High-sensitivity (hs-cTn) assays: CV ≤10% at the 99th percentile AND measurable troponin in >50% of healthy individuals (ideally >95%). The key shift: troponin is measurable at physiological background levels in healthy people, enabling detection of dynamic changes (rise/fall) from an individual's baseline rather than requiring a threshold crossing from "undetectable."

Major validated hs-cTn platforms:

• hs-cTnT (Roche Elecsys): 99th percentile URL = 14 ng/L (sex-specific: ~9 ng/L women, ~14 ng/L men). The most extensively studied assay globally, used in the 0h/1h and 0h/2h ESC algorithm validation studies.
• hs-cTnI (Abbott STAT): 99th percentile URL = 16–34 ng/L depending on sex and manufacturer guidance. Used in the APACE and HIGH-US validation cohorts.
• hs-cTnI (Siemens ADVIA Centaur): Validated for 0h/1h algorithms with different absolute thresholds from Abbott.

Why hs-cTn changed emergency medicine: With conventional assays, troponin was undetectable at presentation in most NSTEMI patients, requiring serial measurements at 0h/3h/6h before a rise could be confirmed. hs-cTn allows the 0h/1h algorithm: if baseline hs-cTn is very low AND the 1-hour delta is minimal, the negative predictive value (NPV) for MI exceeds 99.3%, enabling safe discharge from the emergency department in under 2 hours. Approximately 60–75% of low-risk chest pain patients can be ruled out by the 1-hour algorithm.

Important analytical caveats: Not all hs-cTn assays are interchangeable. The ESC 0h/1h algorithm thresholds (e.g., "below 5 ng/L at 0h" for hs-cTnT) are assay-specific and cannot be directly applied to a different platform. Institutions must use the validated thresholds for their specific assay. Point-of-care hs-cTn devices (e.g., Radiometer AQT90 FLEX) are now available for use when central laboratory turnaround is >60 minutes.

Back to Table of Contents

Reference Ranges and the 99th Percentile

The 99th percentile upper reference limit (URL) is the universally accepted primary decision threshold for myocardial injury. The URL is defined as the troponin concentration at the 99th percentile of a carefully characterized healthy reference population (no cardiovascular disease, no CKD, no medications known to affect troponin).

Sex-Specific Reference Ranges

Women consistently have lower 99th percentile troponin concentrations than men for both hs-cTnT and hs-cTnI. Using a sex-specific URL:

• Increases sensitivity for MI detection in women (who historically were under-diagnosed because they presented with lower absolute troponin values that fell below the sex-neutral threshold).
• Increases specificity in men (avoiding false-positive MI diagnoses due to physiologically higher baseline troponin in men).
• The 2018 Fourth Universal Definition of MI recommends sex-specific URLs where validated.

Typical sex-specific URLs (hs-cTnT Roche Elecsys): women ~9 ng/L, men ~14 ng/L. Using a combined sex-neutral URL of 14 ng/L causes women to be under-diagnosed at the same rate as before hs-cTn was introduced.

Age-Related Changes

The 99th percentile rises significantly with age, even in apparently healthy individuals. This reflects subclinical myocardial injury accumulating from hypertension, subclinical coronary artery disease, left ventricular hypertrophy, and early CKD. Age-specific percentile tables are available for some assays. Clinically, this means that an elderly patient with an hs-cTnT of 20 ng/L (above the standard URL) may have a stable chronic elevation rather than an acute event — requiring the rise/fall delta pattern to distinguish acute from chronic.

The Rise/Fall (Delta) Criterion

A single elevated troponin above the 99th percentile indicates myocardial injury but does not by itself diagnose acute MI. Acute MI requires a rising or falling pattern (dynamic change), indicating an evolving acute process. Key delta thresholds for hs-cTnT:

• 0h/1h algorithm: Absolute delta ≥5 ng/L at 1 hour (combined with 0h value) triggers rule-in; minimal delta (<absolute threshold) combined with low baseline permits rule-out.
• 0h/3h algorithm: Significant change = ≥20% relative change AND absolute change above the minimum detectable difference for the assay.
• Chronic stable elevation: No significant delta across serial measurements, indicating non-acute ongoing myocardial injury (e.g., HF, CKD, stable cardiomyopathy).

Back to Table of Contents

Rapid Rule-In and Rule-Out Algorithms

The 2020 ESC NSTEMI guidelines (Collet et al., PMID: 32860058) define three validated hs-cTn algorithms for emergency chest pain evaluation:

0h/1h Algorithm (Preferred)

Requires two hs-cTn measurements: at presentation (0h) and exactly 1 hour later.

• Rule OUT (safe discharge): 0h hs-cTnT <5 ng/L (very low) AND absolute 1h delta <3 ng/L. NPV >99.3%. Applies to ~60% of patients.
• Rule IN (activate cath lab / cardiology): 0h hs-cTnT ≥52 ng/L OR 1h delta ≥5 ng/L. PPV ~77%.
• Observe zone: Neither criterion met — requires 3h sample and clinical assessment.

The specific ng/L thresholds are assay-dependent. The ESC 0h/1h hs-cTnT thresholds above apply to the Roche Elecsys assay; different values apply to Abbott hs-cTnI and Siemens ADVIA platforms.

0h/2h Algorithm

An alternative when 1-hour follow-up is logistically challenging. Uses two samples at 0h and 2h.

• Rule OUT: Both values below assay-specific low threshold AND delta <absolute change threshold.
• Rule IN: 0h value markedly elevated OR large 2h delta.
• NPV ~99.2%; somewhat lower rule-out efficiency (~50% of patients) compared to the 0h/1h algorithm.

0h/3h Algorithm

The original rapid algorithm, still used where 1h logistics are not established. Uses a fixed 99th percentile threshold plus significant delta (>20% relative change OR >absolute minimum significant change) over 3 hours. NPV ~99.0%.

HEART Score Integration

The HEART Score (History / ECG / Age / Risk factors / Troponin) is a validated 5-component clinical decision tool scoring 0–10. It stratifies chest pain patients into:

• Low risk (0–3): 30-day MACE rate <2%. When combined with an hs-cTn below the 99th percentile at presentation, safe discharge without serial troponin is supported by multiple validation studies.
• Intermediate risk (4–6): Observe; serial troponin + stress testing or CT coronary angiography.
• High risk (7–10): Cardiology consult; invasive coronary angiography.

Back to Table of Contents

Type 1 vs. Type 2 Myocardial Infarction

The Fourth Universal Definition of Myocardial Infarction (Thygesen et al., PMID: 30153967) classifies MI into five types based on pathophysiology, not just troponin levels:

Type 1 MI — Atherosclerotic Plaque Event

Spontaneous MI caused by atherosclerotic plaque rupture, erosion, or fissuring with intraluminal thrombus formation, leading to acute coronary occlusion or reduced coronary blood flow. The "classic" ST-elevation MI (STEMI) or non-STEMI (NSTEMI) pattern. Treatment: urgent revascularization (PCI preferred), dual antiplatelet therapy, anticoagulation, statin, ACE inhibitor/ARB, beta-blocker.

Type 2 MI — Supply-Demand Mismatch

Myocardial injury from a condition other than atherosclerotic plaque disruption that causes supply-demand mismatch. Troponin elevation with a rise/fall pattern is present, but coronary angiography does not reveal a culprit lesion. Common causes:

• Tachyarrhythmia: Atrial fibrillation with rapid ventricular response — rate-related subendocardial ischemia.
• Hypotension/shock: Hemorrhagic shock, distributive shock (sepsis), cardiogenic shock — global supply reduction.
• Severe anemia: Hemoglobin <7 g/dL markedly reduces oxygen-carrying capacity; demand exceeds supply in territories with fixed coronary stenoses.
• Hypertensive emergency: Extreme afterload increase causing subendocardial ischemia.
• Coronary vasospasm: Prinzmetal angina; cocaine-induced vasospasm.
• Pulmonary embolism: Acute right heart pressure overload causing RV free-wall ischemia (see below).

Management of Type 2 MI centers on treating the underlying condition; the benefit of antiplatelet and anticoagulation therapy is less established than in Type 1 MI. This distinction has major therapeutic implications.

Types 3, 4, and 5

• Type 3: Sudden cardiac death with ischemic symptoms and new ECG changes before biomarkers could be obtained (death before blood draw or before results returned).
• Type 4a: MI associated with percutaneous coronary intervention (PCI) — defined as troponin elevation >5× URL within 48 hours of the procedure with ECG or imaging evidence of new ischemia.
• Type 4b: MI caused by stent thrombosis.
• Type 4c: MI related to stent restenosis.
• Type 5: MI associated with coronary artery bypass grafting (CABG) — defined as troponin elevation >10× URL within 48 hours with new Q waves, LBBB, or imaging evidence of new loss of viable myocardium.

Back to Table of Contents

Non-Coronary Causes of Troponin Elevation

Any condition that causes cardiomyocyte injury — regardless of whether coronary arteries are involved — will elevate troponin. Clinicians must integrate troponin findings with the full clinical picture to avoid misdiagnosing every troponin elevation as a coronary MI.

Myocarditis

Inflammation of the myocardium from viral infection (coxsackievirus B, adenovirus, parvovirus B19, SARS-CoV-2, influenza), autoimmune processes (giant cell myocarditis, eosinophilic myocarditis), or toxins (anthracyclines, immune checkpoint inhibitors). Troponin may be markedly elevated. ECG may show diffuse ST elevation mimicking STEMI. Cardiac MRI with late gadolinium enhancement is the key diagnostic tool. Coronary angiography shows normal or non-obstructive arteries.

Pulmonary Embolism

Acute massive or submassive PE causes acute right ventricular pressure overload. The RV free wall — normally perfused at low pressure — sustains subendocardial ischemia when intracavitary pressure abruptly rises. Troponin elevation in PE independently predicts 30-day mortality and is incorporated into risk stratification scores (PESI score, simplified PESI). Elevated troponin in PE is an indication for consideration of systemic thrombolysis or catheter-directed therapy in hemodynamically unstable patients.

Acute Decompensated Heart Failure

Both acute and chronic heart failure are associated with troponin elevation. In acute decompensation, cardiomyocyte injury occurs from subendocardial ischemia (elevated LVEDP compresses subendocardial perfusion), catecholamine excess, and neurohormonal activation. Chronic low-level troponin elevation is a powerful independent predictor of mortality in both HFrEF and HFpEF populations, as demonstrated in the CORONA trial and de Lemos et al. (PMID: 21156950).

Takotsubo (Stress) Cardiomyopathy

Also called apical ballooning syndrome or broken heart syndrome. Massive catecholamine surge (emotional stress, physical stress, post-surgical) causes transient apical wall motion abnormality with ballooning of the LV apex and preserved or hyperdynamic basal function — the characteristic "octopus pot" shape on ventriculography. Troponin is elevated (though often lower than in equivalent-territory STEMI). EF recovers within 4–6 weeks. Coronary angiography shows no obstructive disease. Mimics anterior STEMI clinically and on ECG.

Sepsis-Induced Cardiomyopathy

Direct cardiomyocyte injury from cytokines (TNF-alpha, IL-1beta, IL-6), endotoxin, reactive oxygen species, and nitric oxide mediates a reversible myocardial depression in 10–50% of septic patients. Troponin elevation in sepsis is an independent predictor of ICU mortality. cTnI is preferred over cTnT in sepsis because cTnT shows proportionally higher elevation due to altered renal clearance kinetics in acute kidney injury accompanying sepsis.

CKD and ESRD

Both cTnI and cTnT are chronically elevated in CKD, likely from a combination of reduced clearance, uremia-mediated cardiomyocyte injury, LVH, and high prevalence of subclinical coronary artery disease. cTnT tends to be proportionally more elevated than cTnI in CKD due to molecular weight differences affecting glomerular filtration. In dialysis patients, troponin should be measured serially (0h and 3–6h) to detect dynamic changes over a chronically elevated baseline.

Other Causes

• Cardiac contusion: Blunt chest trauma (motor vehicle accident, defibrillation, direct precordial trauma) — troponin elevation correlates with injury severity and risk of arrhythmia.
• Cardiac ablation and cardioversion: Iatrogenic myocardial injury from electrical or radiofrequency energy.
• Chemotherapy: Anthracyclines (doxorubicin, daunorubicin) cause dose-dependent cardiomyocyte injury; trastuzumab-related cardiomyopathy; immune checkpoint inhibitors can cause fulminant myocarditis with massive troponin elevation (mortality >50% without immunosuppression).
• Rhabdomyolysis: Extreme skeletal muscle injury (trauma, statin myopathy, exertional) can produce sufficient troponin to be detected on some hs-cTnI assays due to residual cross-reactivity; hs-cTnT shows less skeletal muscle cross-reactivity.
• Stroke: Subarachnoid hemorrhage and large hemispheric strokes cause neurogenic cardiac injury through massive catecholamine release — can present with troponin elevation, wall motion abnormalities, and QTc prolongation mimicking MI.
• Hypothyroidism: Severe myxedema can cause troponin elevation from metabolic cardiomyopathy.

Back to Table of Contents

Key Research and Citations

1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–2264. PMID: 30153967
2. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. PMID: 32860058
3. Mueller C, Giannitsis E, Christ M, et al. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med. 2016;68(1):76–87. PMID: 31574243
4. Shah ASV, Anand A, Sandoval Y, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet. 2015;386(10012):2481–2488. PMID: 25728920
5. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858–867. PMID: 19710484
6. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361(9):868–877. PMID: 21475001
7. Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54–61. PMID: 22100995
8. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503–2512. PMID: 21156950
9. Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol. 2011;58(13):1332–1339. PMID: 21641349
10. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254–261. PMID: 19926773
11. Januzzi JL Jr, Mahler SA, Christenson RH, et al. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: AACC Scientific Division and the American College of Cardiology. J Am Coll Cardiol. 2019;73(9):1059–1077. PMID: 28728658
12. Hammarsten O, Fu MLX, Sigurjonsdottir R, et al. Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction. Clin Chem. 2012;58(3):628–637. PMID: 29336604

PubMed Search Links

• High-sensitivity troponin and myocardial infarction diagnosis
• Troponin rapid rule-out algorithm emergency department
• Troponin elevation non-coronary causes
• Type 2 myocardial infarction supply-demand mismatch
• Sex-specific troponin threshold women and men

Back to Table of Contents

Connections

• All Lab Tests
• BNP / NT-proBNP
• D-Dimer
• hs-CRP
• Complete Blood Count
• Ferritin Test
• Cardiac Troponin Panel
• Cardiovascular Disease

Featured Videos